Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.

Trial Profile

Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2015

At a glance

  • Drugs Vadadustat (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Akebia Therapeutics
  • Most Recent Events

    • 07 Nov 2015 Primary endpoint has been met (Change in Week 8 Hemoglobin), according to results published in a company media release.
    • 07 Nov 2015 Results published in the Media Release
    • 28 Oct 2015 Results will be presented at the upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting, as per Akebia Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top